Vyome Acquires Oculo, An AI Startup Launched At The Massachusetts Institute Of Technology And Launched A New Business Unit Focused On Using AI To Tackle Inflammation; Deal Terms Were Undisclosed
Benzinga Newsdesk 1 year ago
M&ANewsHealth CareGeneral
This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI subcommittee comprised of
- This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI subcommittee comprised of Krishna Gupta, Mohanjit Jolly, and Stash Pomichter – all of whom are MIT alumni with deep AI expertise.
- The Oculo transaction will have no bearing on the progress of Vyome's core biotech assets. Vyome remains funded through 2026 to progress its core business.